RAMAT GAN, Israel--(BUSINESS WIRE)--Optimata Ltd. announced today that it has been granted U.S. Patent 7,133,814 for inventing a system that models the development of thrombopoiesis in humans. The invention enables simulating the thrombopoietic process in virtual patients where different therapies are applied. Thrombocytpoienia is a toxic condition that often occurs during cancer treatment. The Optimata invention can be applied to optimize the development of new drugs as well to optimize and personalize the use of existing drugs.
